Skip to main content

Table 1 Sensitivity and specificity of purified and electroeluted antigens with human sera

From: Investigation of the antigenicity and protective efficacy of Leishmania promastigote membrane antigens in search of potential diagnostic and vaccine candidates against visceral leishmaniasis

Purified and electroeluted antigens (kDa)Sensitivity to active VL patients in % (n/N)Sensitivity to 1-month treated VL patients in % (n/N)Sensitivity to 6-month follow-up patients in % (n/N)Specificity to other diseases in % (n’/N)Specificity to healthy samples in % (n’/N)
LAg100 (13/13)84.16 (11/13)0 (0/13)100 (13/13)100 (13/13)
SLA100 (13/13)100 (13/13)7.69 (1/13)100 (13/13)100 (13/13)
31100 (23/23)60 (14/23)26.08 (6/23)39.1 (9/23)100 (23/23)
34100 (23/23)73.91 (17/23)13.04 (3/23)100 (23/23)100 (23/23)
36100 (23/23)69.56 (16/23)78.26 (18/23)40 (8/23)100 (23/23)
45100 (23/23)100 (23/23)60.86 (14/23)30.43 (7/23)60.86 (14/23)
51100 (23/23)91.30 (21/23)30.43 (7/23)100 (23/23)100 (23/23)
63100 (23/23)47.82 (11/23)4.34 (1/23)91.30 (21/23)95.65 (22/23)
72100 (23/23)39.1 (9/23)0 (0/23)65.21 (15/23)73.91 (17/23)
91100 (23/23)8.69 (2/23)0 (0/23)95.75 (22/23)91.30 (21/23)
97100 (23/23)78.23 (18/23)86.95 (20/23)95.75 (22/23)100 (23/23)
  1. Abbreviations: n, no. of positive samples in each group; N, total no. of samples tested in each group; n’, no. of negative samples in each group